English
Home > Products > 1R(3R,4S)-4-(tert-butyldimethylsilyloxy)

China 1R(3R,4S)-4-(tert-butyldimethylsilyloxy) Factory

Our company puts emphasis about the administration, the introduction of talented staff, along with the construction of employees building, seeking hard to boost the standard and liability consciousness of staff members members. Our business successfully attained IS9001 Certification and European CE Certification of 1R(3R,4S)-4-(tert-butyldimethylsilyloxy),CAS NO 701278-56-0,701278-56-0,Entecavir intermediate,Entecavir advance intermediate, Sincerely stay up for serving you from the in the vicinity of future. You are sincerely welcome to go to our company to talk company face to face with each other and create long-term co-operation with us!
1R(3R,4S)-4-(tert-butyldimethylsilyloxy), We strive for excellence, constant improvement and innovation, is committed to make us the "customer trust" and the "first choice of engineering machinery accessories brand" suppliers. Choose us, sharing a win-win situation!

Related Products

Hot Products

  • Ellagic acid

    Ellagic acid

    Product Name:Ellagic acid
    Molecular Formula:C14H6O8
    Molecular Weight;302.19
    CAS Registry Number;476-66-4
  • Clarithromycin lactobionate

    Clarithromycin lactobionate

    Product Name:Clarithromycin lactobionate
    Molecular Formula:C50H89NO24
    Molecular Weight;1088.24
    CAS Registry Number;135326-55-5
  • Losartan

    Losartan

    Product Name:Losartan
    Molecular Formula:C22H23ClN6O
    Molecular Weight:422.91
    CAS Registry Number:114798-26-4
  • 2,5-DIFLUOROANISOLE

    2,5-DIFLUOROANISOLE

    Product Name:2,5-DIFLUOROANISOLE
    Molecular Formula:C7H6F2O
    Molecular Weight:144.12
    CAS Registry Number:75626-17-4
  • FMOC-L-Isoleucine

    FMOC-L-Isoleucine

    Product Name:FMOC-L-Isoleucine
    Molecular Formula:C21H23NO4
    Molecular Weight:353.41
    CAS Registry Number:71989-23-6
  • Dapagliflozin

    Dapagliflozin

    Product Name:Dapagliflozin
    Molecular Formula:C21H25ClO6
    Molecular Weight;408.88
    CAS Registry Number;461432-26-8
  • Related Blog
  • Reviews

  • How to find the best China API manufacturer?

    Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs. The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it.

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    Here are so many diseases that affect the human population in the current hours and so are the numerous drugs that are available to treat those diseases.

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • Bosutinib CAS 380843-75-4

    Chemical name:4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept